BioVie Inc. Files S-1/A Amendment

TL;DR

BioVie Inc. (BIVI) filed an S-1/A amendment, updating its SEC registration. Stay tuned for more details.

AI Summary

BioVie Inc. filed an S-1/A amendment on November 27, 2024, for its registration statement. The company, formerly known as NanoAntibiotics, Inc., is incorporated in Nevada and operates in the Pharmaceutical Preparations sector. The filing provides updated information for its securities registration.

Why It Matters

This filing indicates BioVie Inc. is actively updating its registration with the SEC, which is a necessary step for companies looking to issue or trade securities.

Risk Assessment

Risk Level: medium — S-1/A filings are typically related to securities offerings or significant corporate changes, which inherently carry market risk.

Key Numbers

• 333-283394 — SEC File Number (Identifies the specific registration filing with the SEC.)
• 20241127 — Filing Date (The date the amendment was officially filed with the SEC.)

Key Players & Entities

• BIOVIE INC. (company) — Registrant
• NANOANTIBIOTICS, INC. (company) — Former company name
• Cuong Do (person) — Chief Executive Officer
• 333-283394 (dollar_amount) — SEC File Number
• 20241127 (date) — Filing Date

FAQ

Filing Documents

• bivi_s1a.htm (S-1/A) — 49KB
• bivi_s1aex5z1.htm (EX-5.1) — 18KB
• image_02.jpg (GRAPHIC) — 22KB
• image_03.jpg (GRAPHIC) — 15KB
• 0001520138-24-000434.txt ( ) — 336KB
• bivi-20240930.xsd (EX-101.SCH) — 3KB
• bivi-20240930_def.xml (EX-101.DEF) — 29KB
• bivi-20240930_lab.xml (EX-101.LAB) — 36KB
• bivi-20240930_pre.xml (EX-101.PRE) — 26KB
• bivi_s1a_htm.xml (XML) — 5KB

Exhibits

Item 16. Exhibits . (a) Exhibits. Exhibit Number Description of Document 2.1 Agreement and Plan of Merger, dated April 11, 2016, among the Company, LAT Acquisition Corp and LAT Pharma, LLC (incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed on April 15, 2016). 3.1 Articles of Incorporation of the Company as filed with the Secretary of State of Nevada (incorporated by reference to Exhibit 3.1 to the Company's registration statement on Form S-1 filed on August 15, 2013, File No. 333-190635). 3.2 Certificate of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on July 22, 2016). 3.3 Certificate of Amendment to Articles of Incorporation (incorporated by reference to Appendix A to the Company's Information Statement on Schedule 14C filed on July 13, 2018). 3.4 Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on July 3, 2018). 3.5 Certificate of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.6 to the Company's registration statement on Form S-1 filed on November 22, 2019, File No. 333-231136). 3.6 Certificate of Change (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on August 1, 2024) 3.7 Termination of Amendment/Certificate (incorporated by reference to Exhibit 3.1 to the Company's Current Report, as amended, on Form 8-K/A filed on August 6, 2024) 3.8 Certificate of Amendment (incorporated by reference to Exhibit 3.1 to the Company's Current Report, as amended, on Form 8-K/A filed on August 6, 2024) 3.9 Amended and Restated Bylaws of the Company, dated June 16, 2020 (incorporated by reference to Exhibit 3.5 to the Company's Quarterly Report on Form 10-Q filed on November 10, 2021). 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Carson BIOVIE INC. By: /s/ Cuong Do Cuong Do Chief Executive Officer Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated. Person Capacity Date /s/ Cuong Do Chief Executive Officer November 27, 2024 Cuong Do (Principal Executive Officer) /s/ Joanne Wendy Kim Chief Financial Officer November 27, 2024 Joanne Wendy Kim (Principal Financial and Accounting Officer) * Chairman November 27, 2024 Jim Lang * Director November 27, 2024 Michael Sherman * Director November 27, 2024 Richard J. Berman * Director November 27, 2024 Robert Hariri * Director November 27, 2024 Sigmund Rogich Pursuant to Power of Attorney By: /s/ Cuong Do Cuong Do Attorney-in-Fact

View Full Filing

View this S-1/A filing on SEC EDGAR